Migraine is a primary episodic headache disorder that represents a substantial burden and disability worldwide. Its pathogenesis is multifactorial and remains hitherto poorly elucidated. An interesting but less-well-known association is that between migraine and gastrointestinal disorders. We have reviewed the literature for relevant papers reporting on the clinical association between migraine and gastrointestinal symptoms. Several studies have shown different gastrointestinal diseases to be associated with migraine, but the underlining pathophysiology remains elusive. The data gathered and analyzed have shown great variability across studies, making it impossible to draw definitive conclusions. Further research is required to elucidate this potential relationship. An understanding of the relationship between migraine and gastrointestinal disorders is of great clinical importance for prompt diagnosis and treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532317 | PMC |
| http://dx.doi.org/10.3988/jcn.2017.13.3.215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular regulatory effect of the ergot alkaloid methylergometrine on the α3β4 nicotinic acetylcholine receptor.
Biochem Biophys Res Commun
December 2024
Department of Biotechnology and Department of Integrative Food, Bioscience and Biotechnology (BK21 FOUR), Chonnam National University, Gwangju, 61186, South Korea. Electronic address:
Methylergometrine has widely been used pharmacologically to treat conditions such as pain, addiction, vasoconstriction, migraines, and Parkinson's disease. Despite its side effects, it is used as a therapeutic agent and research material for various diseases based on its natural potential; however, the regulatory effect of its interaction with the nicotinic acetylcholine receptor (nAChR) has not yet been investigated. The α3β4 nAChR is an ion channel essential for neurotransmission within the sympathetic, parasympathetic, and autonomic nervous systems.
View Article and Find Full Text PDFNutraceuticals: a promising, yet unregulated Frontier in Healthcare.
Eur J Clin Nutr
December 2024
Faculty of Data Science, Musashino University, Tokyo, Japan.
Nutraceuticals, with their potential health benefits, are increasingly being used to manage a variety of health conditions. The global market for nutraceuticals, valued at USD 540 billion in 2022, is projected to reach USD 1025 billion by 2030. This paper delves into the beneficial impacts of emerging nutraceuticals on a spectrum of medical disorders, drawing from credible sources from the National Library of Medicine.
View Article and Find Full Text PDFShared Genetics of Migraine and Gastrointestinal Disorders Implicates Underlying Neurologic Mechanisms Yet Heterogeneous Etiologies.
Neurol Genet
December 2024
From the Division of Preventive Medicine (D.I.C., Y.G., P.M.R.), Brigham and Women's Hospital and Harvard Medical School; and the Clinical and Translational Epidemiology Unit (A.T.C., K.S.) and Division of Gastroenterology (A.T.C., K.S.), Massachusetts General Hospital, and Harvard Medical School, Boston, MA.
Background And Objectives: Migraine is strongly comorbid with irritable bowel syndrome (IBS), one of several gastrointestinal (GI) conditions that are distinguished by symptomatic profiles that are partly overlapping. Potential shared mechanisms of migraine and the GI conditions were investigated by assessing shared genetics on a genome-wide basis.
Methods: Analyses leveraged genome-wide summary statistics from large-scale genetic studies for migraine, including by aura status, IBS, peptic ulcer disease (PUD), gastrointestinal reflux (GERD), functional dyspepsia (FD), diverticular disease (DD), and the immune-related inflammatory bowel disease (IBD) or its constituents, ulcerative colitis (UC) and Crohn disease (CD).
Similarities and differences in self-reported symptoms and comorbidities between hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders.
Rheumatol Adv Pract
November 2024
Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.
Objectives: Patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) experience a wide array of symptoms and system disorders. This study aimed to identify whether differences occurred in 115 self-reported symptoms and comorbidities in patients diagnosed with hEDS or HSD.
Methods: In this study we analysed self-reported data from an EDS Clinic intake questionnaire in patients diagnosed with hEDS, HSD or no hypermobile conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!